个性化文献订阅>期刊> ACS Medicinal Chemistry Letters
 

Discovery of CS-0777: A Potent, Selective, and Orally Active S1P(1) Agonist

  作者 NISHI TAKAHIDE; MIYAZAKI SHOJIRO; TAKEMOTO TOSHIYASU; SUZUKI KEISUKE; IIO YUKIKO; NAKAJIMA KATSUYOSHI; OHNUKI TAKASHI; KAWASE YUMI; NARA FUTOSHI; INABA SHINICHI; IZUMI TAKASHI; YUITA HIROSHI; OSHIMA KEIKO; DOI HIROMI; INOUE RYOTAKU; TOMISATO WATARU; KAGARI TAKASHI; SHIMOZATO TAKAICHI  
  选自 期刊  ACS Medicinal Chemistry Letters;  卷期  2011年2-5;  页码  368-372  
  关联知识点  
 

[摘要]CS-0777 (3) is phosphorylated in vivo, and the phosphate of CS-0777 (CS-0777-P) (4) acts as a selective S1P receptor-1 (S1P(1)) modulator. We report herein the synthesis of CS-0777 and CS-0777-P, pharmacological effects such as S1P(1) and S1P(3) agonist activity in vitro, peripheral blood lymphocyte lowering effects and the suppressive effect on experimental autoimmune encephalomyelitis (EAE), and also the pharmacokinetics in rats. CS-0777-P had similar to 320-fold greater agonist activity for human S1P(1) (EC50; 1.1 nM) relative to S1P(3) (EC50; 350 nM). Following administration of single oral doses of 0.1 and 1 mg/kg of CS-0777 in rats, lymphocyte counts decreased significantly, with a nadir at 12 h postdose and recovery to vehicle control levels by 5 days postdose. In the EAR model compared to the vehicle-treated group, significant decreases in the cumulative EAE scores were observed for the 0.1 and 1 mg/kg CS-0777 groups in rats. CS-0777 is currently in clinical trials for the treatment of multiple sclerosis (MS).

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内